Journal of cardiology and cardiovascular sciences最新文献

{"title":"Protective Effects of Angiotensin-Converting-Enzyme-2 on Renal Dysfunction in Obstructive Jaundice","authors":"Feixiang Wu","doi":"10.29245/2578-3025/2018/5.1146","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/5.1146","url":null,"abstract":"","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48232395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary: \"Single Center Experience with the AngioVac Aspiration System.\"","authors":"J. Salsamendi, Yi Chang","doi":"10.29245/2578-3025/2018/5.1152","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/5.1152","url":null,"abstract":"© 2018 Chang YS. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License. Venous thromboembolism (VTE), which includes Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) is the third most frequent cardiovascular disease1,2. VTE is a condition which affects all patients regardless of age, gender and ethnicity. It is estimated to have an annual incidence which ranges from 104-183 per 100,000 person-years, similar to that of stroke. The variation of incidence rates may depend on multiple factors including age distribution and ethnicity, and the risk factors exposed by the patient population3-15. The important risk factors for VTE include increasing age, high body mass index, male gender, malignancy, immobilization, oral contraceptive pills, pregnancy, and coagulopathies. Due to its high recurrence rate and the patient population at risks who often presents with multiple comorbid conditions, VTE results in a healthcare financial burden of $10 billion annually in the United States2. It is undoubtedly a major public health concern with the burden of disease affecting both developed and developing nations. Untreated VTE often presents with chronic and potentially lifethreatening complications such as post-thrombotic syndrome (PTS) and chronic thromboembolism pulmonary hypertension (CTEPH). CTEPH is reported as a complication in 3.8% of patients who experienced acute pulmonary embolism and is associated with significant morbidity and mortality16. PTS occurs in 20%-50% of the patients, presenting with clinical manifestations of chronic leg pain, edema and ischemic ulcers; negatively impacting the quality of life for the patients17. American Heart Association recommends warfarin remains as the first line treatment for acute proximal DVT to prevent recurrence and PE; American College of Chest Physicians guideline suggests non-vitamin K antagonist being the first line18,19. Additionally, Larsen et al reported patient-self-management of oral anticoagulation promotes treatment adherence leading to decreased recurrence of DVT among those patients20. However, 20-50% of patients continue to develop PTS with adequate oral anticoagulant21. Early en-bloc removal of the thrombus is preferred by using catheterdirected therapy. Recent studies suggest the potential benefits of early thrombus removal in restoring venous patency and valvular competency22. The conventional surgical management of VTE is of historical value now; with the advent of pharmacomechanical thrombolysis and catheter-directed thrombolysis which may be more efficient with fewer bleeding complications.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41528891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thrombophilia, Platelet von Willebrand Factor Mediated Arteriolar Microvascular Thrombosis in JAK2V617F Mutated Thrombocythemia and Acquired ADAMTS13 Deficiency as Causes of Intrahepatic Obstructive Microvascular Liver Diseases in Budd-Chiari Syndrome and Splanchnic Vein Thrombosis","authors":"J. Michiels, P. Dulíček, Z. Berneman, A. Gadisseur, W. Schroyens","doi":"10.29245/2578-3025/2018/5.1154","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/5.1154","url":null,"abstract":"Page 33 of 45 Venous Thrombophilia, Platelet von Willebrand Factor Mediated Arteriolar Microvascular Thrombosis in JAK2V617F Mutated Thrombocythemia and Acquired ADAMTS13 Deficiency as Causes of Intrahepatic Obstructive Microvascular Liver Diseases in Budd-Chiari Syndrome and Splanchnic Vein Thrombosis Jan Jacques Michiels1,3*, Petr Dulicek2, Zwi Berneman1, Alain Gadisseur1, Wilfried Schroyens1 1Departments of Hematology and Coagulation Research, University Hospital Antwerp, Belgium 2Fourth Department of Internal Medicine–Hematology, University Hospital in Hradec Kralove and Charles University Prague, Faculty of Medicine in Hradec Kralove and Prague, Czech Republic on behave of the Central European Vascular Forum: CEVF 3Blood, Coagulation and Cardiovascular Medicine Research Center and International Collaboration and Academic Research on Myeloproliferative Neoplasms: ICAR.MPN, Goodheart Institute & Foundation in Nature Medicine & Health, Rotterdam, The Netherlands","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41917660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Coronary Plaque in Psoriasis and the Impact of Current Therapies","authors":"A. Menter","doi":"10.29245/2578-3025/2018/5.1149","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/5.1149","url":null,"abstract":"Psoriasis is a systemic inflammatory disease which contributes to an increased risk for cardiovascular disease, specifically coronary artery disease. Patients with psoriasis tend to have greater total coronary plaque burden and more high risk plaque than healthy controls. This likely contributes to the higher rate of myocardial infarction and 4-5 year reduction in lifespan observed in our psoriasis population. With biologic therapy and improvement in PASI scores, total plaque burden and noncalcified coronary plaque decreases as well. Specifically, ustekinumab decreases intima-media thickness and reduces vascular inflammation. Likewise, TNF-α inhibitors decrease vascular inflammation and reduce cardiovascular events in both sexes, and reduce coronary plaque formation in men with psoriasis. This may be due to elevation in glycoprotein acetylation, which is associated with cardiovascular events and elevated in psoriasis. This elevation has also been shown to decrease with adalimumab usage. Despite all of the knowledge gained on this topic, the incidence of myocardial infarction in psoriasis patients currently remains unchanged when compared to prior years. Consequently, we emphasize the need for further research on the unique pathogenesis of psoriatic coronary plaque formation as well as the effect biologic agents have on this coronary plaque in order to improve the wellbeing of this patient population.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48529471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary: Predicting Outcomes in Patients with Asymptomatic Moderate to Severe Aortic Stenosis","authors":"R. Bahler","doi":"10.29245/2578-3025/2018/5.1157","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/5.1157","url":null,"abstract":"","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47364591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review Article: The Effect of Performing a Paracentesis on Hospital Outcomes","authors":"L. Sobotka","doi":"10.29245/2578-3025/2018/5.1153","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/5.1153","url":null,"abstract":"Decompensated cirrhosis with ascites results in high health care expenditures, 30 day readmission, morbidity, and mortality. Paracentesis is indicated in patients with cirrhosis and ascites to rule out spontaneous bacterial peritonitis and for symptomatic control. Performing at least a diagnostic paracentesis has been proved to reduce inpatient mortality; however, the procedure was also associated with longer length of stay, higher costs during hospitalization and increased risk of 30-day readmission. In summary, diagnostic paracentesis is crucial to rule out infection, but other interventions should be utilized to control ascites, as worse hospital outcomes as likely associated with a large volume paracentesis.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46953235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anthracycline and Trastuzumab-Based Therapy in Early Stage Breast Cancer: Do the Data Justify Cardiac Surveillance?","authors":"C. Shapiro","doi":"10.29245/2578-3025/2018/4.1136","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/4.1136","url":null,"abstract":"Anthracycline-based and trastuzumab-containing regimens make a significant impact on reducing the risk of distant metastases and improving cause-specific and overall survival in early stage breast cancer. However, these regimens may cause cardiomyopathy during and after treatment. Despite anthracyclines being in use for nearly fifty years, there are no evidence-based guidelines for cardiac surveillance in asymptomatic breast cancer survivors. In fact, the current guidelines for cardiac monitoring while on trastuzumab therapy were from clinical trials, with empiricism and not data informing the recommendations for cardiac monitoring.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45792453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dichotomous Role of N-methyl-D-Aspartate Receptors in Ischemic Stroke","authors":"R. Balsara","doi":"10.29245/2578-3025/2018/4.1133","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/4.1133","url":null,"abstract":"","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":"82 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41277488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary: A New Model for Chronic Care to Improve Patient's Skill","authors":"Patrick Dunn, S. Conard","doi":"10.29245/2578-3025/2018/4.1138","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/4.1138","url":null,"abstract":"© 2018 Dunn P. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License. More effective treatment and increased survival from acute cardiometabolic conditions, such as heart attack and stroke, and an aging population has resulted in more people living with chronic conditions, such as coronary artery disease, heart failure, hypertension, high cholesterol, diabetes, and obesity1. With increased incentives to focus on the long-term outcomes of patients, we believe that there is an even greater need for more effective models for chronic care, both in research and in clinical practice2. Current approaches for increasing patient involvement range from low tech and low touch to high tech and high touch interventions that are delivered inconsistently and ineffectively. In cardiovascular disease and diabetes these approaches include formal and informal educational methods, print and digital media, apps and wearables that track activity blood pressure, weight, and glucose, and disease management programs such as cardiac rehabilitation and diabetes self-management programs3. Ultimately, high impact models are challenging to deliver in a clinical setting due to operational, resource, and reimbursement challenges.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47366270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dilemma of Complete Coronary Revascularization","authors":"C. Aurigemma","doi":"10.29245/2578-3025/2018/4.1137","DOIUrl":"https://doi.org/10.29245/2578-3025/2018/4.1137","url":null,"abstract":"The CR is achieved more commonly with coronary artery by-pass (CABG) than with percutaneous coronary intervention (PCI). In this regard, the possibility of achieving CR is one of variable that should be factored when deciding the optimal strategy of revascularization between PCI and CABG in patients with multivessel coronary artery disease. However clinical features, such as patient’s age, life expectancy, symptoms at presentation, comorbidities and left ventricular function may increase the morbidity or mortality risk of CABG intervention and a “reasonable” incomplete revascularization (IR) achieved with PCI may be a better choice in particular clinical subset.","PeriodicalId":93019,"journal":{"name":"Journal of cardiology and cardiovascular sciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46925832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}